{
    "clinical_study": {
        "@rank": "104472", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of erlotinib in treating patients who have\n      unresectable liver, bile duct, or gallbladder cancer. Biological therapies such as erlotinib\n      may interfere with the growth of cancer cells and slow the growth of the tumor."
        }, 
        "brief_title": "Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer", 
        "condition": [
            "Adult Primary Cholangiocellular Carcinoma", 
            "Adult Primary Hepatocellular Carcinoma", 
            "Advanced Adult Primary Liver Cancer", 
            "Cholangiocarcinoma of the Extrahepatic Bile Duct", 
            "Cholangiocarcinoma of the Gallbladder", 
            "Localized Unresectable Adult Primary Liver Cancer", 
            "Recurrent Adult Primary Liver Cancer", 
            "Recurrent Extrahepatic Bile Duct Cancer", 
            "Recurrent Gallbladder Cancer", 
            "Unresectable Extrahepatic Bile Duct Cancer", 
            "Unresectable Gallbladder Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Gallbladder Neoplasms", 
                "Bile Duct Neoplasms", 
                "Cholangiocarcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the proportion of patients with unresectable hepatocellular or biliary\n      carcinoma treated with OSI-774 who are progression-free at 24 weeks.\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the toxicity profile of this treatment in each of the patient groups.\n\n      II. To evaluate the objective response rate of patients with hepatocellular or biliary\n      carcinoma treated with OSI-774.\n\n      III. To evaluate overall and progression-free survival. IV. To assess the EGFR protein\n      levels and explore their association with clinical outcome.\n\n      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups according to\n      cancer type (hepatocellular vs biliary).\n\n      Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6\n      courses in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months for up to 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed hepatocellular carcinoma (HCC) or biliary\n             carcinoma that is surgically unresectable; exception: for surgically unresectable\n             HCC, a hypervascular mass on CT and an AFP > 100ng/mL will suffice as noninvasive\n             diagnostic criteria\n\n          -  Measurable disease defined as at least one lesion whose longest diameter can be\n             accurately measured as \u2265 2.0 cm\n\n          -  Absolute neutrophil count (ANC) \u2265 1500/mm3\n\n          -  PLT \u2265 75,000/mm3\n\n          -  Total bilirubin \u2264 2 x upper normal limits (UNL)\n\n          -  Serum AST \u2264 3 x UNL\n\n          -  Serum ALT \u2264 3 x UNL\n\n          -  Serum creatinine \u2264 2 mg/dL\n\n          -  Serum albumin \u2265 2.5 g/dL\n\n          -  Patients not receiving anticoagulation: INR \u2264 1.5\n\n          -  ECOG performance status (PS) 0, 1, or 2\n\n          -  Estimated life expectancy \u2265 3 months\n\n          -  Capable of understanding the investigational nature, potential risks and benefits of\n             the study and able to provide written informed consent\n\n          -  HCC Patients Only: Child-Pugh classification of A or B\n\n          -  For patients having prior cryotherapy, radiofrequency ablation, ethanol injection, or\n             photodynamic therapy, the following criteria must be met:\n\n               -  > 6 weeks has elapsed since that therapy\n\n               -  Indicator lesion(s) is/are outside the area of prior treatment or, if the only\n                  indicator lesion is inside the prior treatment area, there must be clear\n                  evidence of disease progression associated with that lesion\n\n               -  Edges of the indicator lesion are clearly distinct on CT scanning\n\n        Exclusion Criteria:\n\n          -  Ampulla of Vater tumors\n\n          -  Any of the following as this regimen may be harmful to a developing fetus or nursing\n             child:\n\n               -  Pregnant women\n\n               -  Breastfeeding women\n\n               -  Men or women of childbearing potential or their sexual partners who are\n                  unwilling to employ adequate contraception (condoms, diaphragm, birth control\n                  pills, injections, intrauterine device [IUD], surgical sterilization,\n                  subcutaneous implants, or abstinence, etc.)\n\n               -  NOTE: The effects of OSI-774 on the developing human fetus at the recommended\n                  therapeutic dose are unknown\n\n          -  Any of the following:\n\n               -  > 1 prior systemic anticancer therapy; Note: Chemoembolization will be\n                  considered as one prior chemotherapeutic regimen.\n\n               -  Prior EGFR targeting therapy\n\n               -  Nitrosoureas or mitomycin C \u22646 weeks prior to study entry\n\n               -  Other chemotherapy \u22644 weeks prior to study entry\n\n                  \u2022 Immunotherapy \u2264 4 weeks prior to study entry\n\n               -  Biologic therapy \u2264 4 weeks prior to study entry\n\n               -  Radiation therapy \u2264 4 weeks prior to study entry\n\n               -  Prior cryotherapy, radiofrequency ablation, ethanol injection or photodynamic\n                  therapy \u22646 weeks prior to study entry\n\n               -  Failure to fully recover from adverse effects of prior therapies regardless of\n                  interval since last treatment\n\n               -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy\n                  or supportive care considered investigational\n\n               -  Major surgery, or significant traumatic injury occurring \u2264 3 weeks prior to\n                  planned treatment start date\n\n          -  Any of the following:\n\n               -  Gastrointestinal tract disease resulting in an inability to take oral medication\n\n               -  Requirement for IV alimentation\n\n               -  Prior procedures affecting absorption\n\n               -  Active peptic ulcer disease\n\n          -  History of other malignancy other than hepatocellular or biliary carcinoma within the\n             previous 3 years, except for adequately treated basal cell or squamous cell skin\n             cancer, or carcinoma of the cervix\n\n          -  Known abnormalities of the cornea such as:\n\n               -  History of dry eye syndrome or Sjorgen's syndrome\n\n               -  Congenital abnormality (e.g., Fuch's dystrophy)\n\n               -  Abnormal slit-lamp examination using a vital dye (e.g., fluorescein,\n                  Bengal-Rose)\n\n               -  Abnormal corneal sensitivity test (Schirmer test or similar tear production\n                  test)\n\n          -  Known CNS metastases; NOTE: These patients are excluded from this clinical trial\n             because of their poor prognosis and because they often develop progressive neurologic\n             dysfunction that would confound the evaluation of neurologic and other adverse events\n\n          -  Uncontrolled intercurrent illness including, but not limited to:\n\n               -  Ongoing or active infection\n\n               -  Symptomatic congestive heart failure\n\n               -  Unstable angina pectoris, cardiac arrhythmia\n\n               -  Psychiatric illness/social situations that would limit compliance with study\n                  requirements\n\n          -  HIV-positive patients receiving combination anti-retroviral therapy; NOTE: Patients\n             with immune deficiency are at increased risk of lethal infections when treated with\n             marrow-suppressive therapy; these patients are excluded from the study because of\n             possible pharmacokinetic interactions with OSI-774; appropriate studies will be\n             undertaken in patients receiving combination antiretroviral therapy when indicated"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00033462", 
            "org_study_id": "NCI-2012-02797", 
            "secondary_id": [
                "MC0152", 
                "5429", 
                "N01CM17104"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "description": "Given orally", 
                "intervention_name": "erlotinib hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CP-358,774", 
                    "erlotinib", 
                    "OSI-774"
                ]
            }, 
            {
                "arm_group_label": "Arm I", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Philip Philip", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Confidence intervals for the true PFR will be calculated using the methods of Duffy-Santner.", 
            "measure": "Proportion of patients who are progression-free at 24 weeks", 
            "safety_issue": "No", 
            "time_frame": "At 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00033462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response, defined by the RECIST criteria in terms of tumor/lesion size and change", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "The distribution of survival time will be estimated using the method of Kaplan-Meier.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to death due to any cause, assessed up to 3 years"
            }, 
            {
                "description": "The distribution of time to progression will be estimated using the method of Kaplan-Meier.", 
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to documentation of disease progression, assessed up to 3 years"
            }, 
            {
                "description": "We will evaluate these EGFR protein levels and explore their association with clinical outcome.", 
                "measure": "EGFR protein levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Analyses will be done independently on patients from each patient group. Corresponding 95% confidence intervals will also be calculated.", 
                "measure": "Overall response rate in EGFR positive patients", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Mayo Clinic": "44.022 -92.47"
    }
}